Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 15/20 | 0.78 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.78 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.78 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.78 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.78 |
| ▸ | ACVR1B | P36896 | 3/20 | 0.73 |
| ▸ | MAPT | P10636 | 4/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.72 |
| ▸ | HPGD | P15428 | 3/20 | 0.72 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.72 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.72 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.72 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.72 |
| ▸ | CSNK1E | P49674 | 2/20 | 0.72 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.72 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.72 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.72 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28825919 | 0.91 | TGFBR1 (0.82) | TGFBR1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL5139175 | 0.88 | TGFBR1 (0.79) | TGFBR1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL373802 | 0.88 | TGFBR1 (1.00) | TGFBR1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL373248 | 0.85 | TGFBR1 (1.00) | TGFBR1MAPK14MAPK13MAPK12MAPK11 | |
| Sb-431542 SCHEMBL29432843 | 0.85 | TGFBR1 (0.98) | TGFBR1MAPK14MAPK13MAPK12MAPK11 | |
| Sb-431542 SCHEMBL2681356 | 0.85 | TGFBR1 (0.98) | TGFBR1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL373558 | 0.85 | TGFBR1 (1.00) | TGFBR1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL23352241 | 0.84 | TGFBR1 (0.73) | TGFBR1MAPK14MAPK13MAPK12MAPK11 | |
| Sb-431542 SCHEMBL310028 | 0.84 | TGFBR1 (1.00) | TGFBR1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL4084980 | 0.84 | TGFBR1 (0.71) | TGFBR1MAPK14MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11987558-B1 | ALK5 inhibitors and their uses | SYNTHIS THERAPEUTICS, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| US-20230132568-A1 | ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | SYNTHIS THERAPEUTICS, INC. (US) | 2023-05-04 | — | — | US | disclosed |
| US-20230090552-A1 | ALK5 INHIBITOR CONJUGATES AND USES THEREOF | SYNTHIS THERAPEUTICS, INC. (US) | 2023-03-23 | — | — | US | disclosed |
| US-11583593-B2 | Antibody-ALK5 inhibitor conjugates and their uses | SYNTHIS THERAPEUTICS, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-20210299268-A1 | ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | SYNTHIS THERAPEUTICS, INC. (US) | 2021-09-30 | — | — | US | disclosed |
| US-20200147234-A1 | ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | SYNTHIS, LLC (US) | 2020-05-14 | — | — | US | disclosed |
| EP-1169317-A1 | TRIARYLIMIDAZOLES | SMITHKLINE BEECHAM CORPORATION (US) | 2002-01-09 | — | — | EP | disclosed |
| WO-2000061576-A1 | TRIARYLIMIDAZOLES | SMITHKLINE BEECHAM CORPORATION (US) | 2000-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11987558-B1 | ALK5 inhibitors and their uses | ALK, ALKBH3, ALKBH5 | TGFBR1 106/4885MAPK14 1923/4885MAPK13 1165/4885 |
| US-20210299268-A1 | ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | ALK, ALKBH5, ALKBH3 | TGFBR1 528/4885MAPK14 2643/4885MAPK13 1936/4885 |
| US-20230090552-A1 | ALK5 INHIBITOR CONJUGATES AND USES THEREOF | ALK, ALKBH5, ALKBH3 | TGFBR1 75/4885MAPK14 1174/4885MAPK13 734/4885 |
| US-11583593-B2 | Antibody-ALK5 inhibitor conjugates and their uses | ALK, ALKBH5, ALKBH3 | TGFBR1 528/4885MAPK14 2643/4885MAPK13 1936/4885 |
| US-20200147234-A1 | ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | ALK, ALKBH5, ALKBH3 | TGFBR1 528/4885MAPK14 2643/4885MAPK13 1936/4885 |
| US-20230132568-A1 | ANTIBODY-ALK5 INHIBITOR CONJUGATES AND THEIR USES | ALK, ALKBH5, ALKBH3 | TGFBR1 528/4885MAPK14 2643/4885MAPK13 1936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.